Amolyt Pharma specializes in developing innovative therapeutic peptides to treat rare endocrine and metabolic diseases. Throughout its successful journey, 4Reliance has served as a trusted advisor. 4Reliance acted as the exclusive advisor for Amolyt’s €67M Series A round, provided focused guidance during its $80M Series B and $138M Series C rounds, and offered strategic advice on Amolyt’s $1 billion acquisition by AstraZeneca.

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare ocular and CNS (Central Nervous System) diseases. 4Reliance advised Coave on its €33M series B. 

Cognivia is an innovative R&D company developing patient solutions through personalized treatment refinement. The company notably developed Placebell, a solution allowing the characterization of the individual placebo response of patients involved in clinical studies. 4Reliance partners with Cognivia on a long term “strategic growth” approach. 4Reliance is playing an integrated role with Cognivia to advise on strategic decisions including on raising over 21M€ financing to date.

Secoya is a spin-off from the Brussels ULB university having developed at a mature level innovative production technologies serving the pharmaceutical industry. 4Reliance is acting a co-founder of the company and advised on 2 successive financing rounds of €1.5M and €1,0m with long-term oriented investors.

4Reliance advised Tilman, a family-owned Belgian laboratory specializing in plant-based medicines, in securing a strategic €5 million investment from Whitestone Group.

Keranova designs and develops surgical equipment for various ophthalmologic indications involving the anterior segment of the eye.
4Reliance advised in 2019 on its €24M series B.

ImmuPharma is a UK incorporated biotech listed on the the AIM with a portfolio including a Phase 3 candidate against the Lupus disease and a peptide technology platform developed in Bordeaux in collaboration with the CNRS.
4Reliance advised in 2019 on its dual listing on Euronext Brussels.

Enyo Pharma develops innovative drug candidates by mimicking virus strategies to modulate host cellular functions. The Series B led by US investor, Orbimed, will finance two phase II of its lead product in chronic HBV and NASH.
4Reliance advised on its €40M series B.

Founded by a Neurologist, Medday’s lead product is designed to treat patients that suffer from the progressive form of Multiple Scloerosis, a disease where no treatment existed and epresents a $15 bn market potential.
4Reliance advised on its €34M series B.

DBV has revolutionized the field of immunology by demonstrating that the immune system can be accessed through the skin using a patch. Its first focus is to provide a treatment for patients suffering from peanut allergy.
4Reliance advised on 2 critical financing (last private financing and its Euronext IPO). The company then continued its path of scientific and financial success as its listing on Nasdaq to raise $200M highlighted.

CoreValve is one of the biggest European success story in Medtech. Its technology eliminates the need to do open-heart surgery to replace defaulting heart valves.
4Reliance advised on 2 private financing rounds €4.5M Series A and €20M series B). Continued to advise the founder up to the $850M acquisition by Medtronic.

Persee Medica’s shareholders decided to sell their business just when two products where launched: Silence (anti-snoring) and Cyclamax (sleep).
4Reliance advised the shareholders on the sale of the company to Omega-Pharma. Acquired product became top sales products for Omega-Pharma (subsequently acquired by Perrigo).

Earlens introduced a breakthrough with a light-driven hearing aid. The technology provides natural and rich sound with a full spectrum, making hearing possible in a noisy environment.
4Reliance advised on a critical bridge financing subscribed by selected European investors.

Adocia specializes in the development of innovative formulations of already-approved therapeutic proteins.
4Reliance advised on a critical €14M top-up equity financing from an internal round. The company then went to do an IPO on Euronext and signed major deals with pharma companies.